Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial) – A phase II non-randomised trial-Reference-Cited by-同舟云学术

Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial) – A phase II non-randomised trial

Published:2014-12 Issue:18 Volume:50 Page:3107-3115
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Mitry Emmanuel,Walter Thomas,Baudin Eric,Kurtz Jean-Emmanuel,Ruszniewski Philippe,Dominguez-Tinajero Sophie,Bengrine-Lefevre Leïla,Cadiot Guillaume,Dromain Clarisse,Farace Françoise,Rougier Philippe,Ducreux Michel

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference34 articles.

1. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States;Yao;J Clin Oncol,2008

2. Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors;Turaga;CA Cancer J Clin,2011

3. A new era for the systemic therapy of neuroendocrine tumors;Eads;Oncologist,2012

4. Prospective, Randomized, Multicenter Trial on the Antiproliferative Effect of Lanreotide, Interferon Alfa, and Their Combination for Therapy of Metastatic Neuroendocrine Gastroenteropancreatic Tumors—The International Lanreotide and Interferon Alfa Study Group

5. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group;Rinke;J Clin Oncol,2009

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well‐differentiated small intestine neuroendocrine tumours;Journal of Neuroendocrinology;2024-07-08

2. Targeted Therapies;Neuroendocrine Tumours;2024

3. Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group;The Oncologist;2023-09-07

4. Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): What is the recent evidence?;Best Practice & Research Clinical Endocrinology & Metabolism;2023-09

5. Combination Systemic Therapies in Advanced Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Comprehensive Review of Clinical Trials and Prospective Studies;Biology;2023-07-30